Argireline (Acetyl Hexapeptide-8)

What it is

Argireline (Ac-EEMQRR-NH2) is a synthetic hexapeptide patterned from the N-terminal end of SNAP-25. Its primary proposed mechanism is interference with the formation and/or stability of the SNARE complex required for Ca2+-dependent exocytosis, thereby inhibiting neurotransmitter release at the neuromuscular junction and reducing facial muscle contractions that cause dynamic wrinkles. It has been described as a competitive SNAP-25 inhibitor. In vitro studies showed that Argireline significantly inhibited neurotransmitter release with a potency similar to botulinum toxin A, but with much lower efficacy than the neurotoxin. It is also reported to inhibit catecholamine release and to prevent vesicle docking by blocking ternary SNARE complex formation. Animal studies demonstrated improved histological skin structure and increased type I collagen with decreased type III collagen after topical application (PMID 23464592, PMID 23607739). In a 3D-bioengineered human skeletal muscle model, the Argireline® Amplified peptide was shown to cause muscle relaxation in both healthy and aged tissue. The peptide also demonstrates affinity toward Cu(II) ions, forming coordination complexes whose cosmetic significance is under study.

Class: Synthetic cosmeceutical hexapeptide / neuromuscular signaling inhibitor (SNARE complex competitor)

What it's studied for

• Reduction of facial wrinkles / anti-aging (topical) Mixed
  • 10% O/W emulsion applied to healthy women volunteers reduced wrinkle depth up to 30% after 30 days of treatment. No in vivo oral toxicity or primary irritation observed at high doses. PMID 18498523 Blanes-Mira C et al. Int J Cosmet Sci. 2002.
  • Randomized, double-blind, placebo-controlled RCT in 60 Chinese subjects (3:1 argireline:placebo). Argireline applied twice daily for 4 weeks to peri-orbital wrinkles showed 48.9% total anti-wrinkle efficacy vs 0% in placebo; objective roughness parameters significantly decreased (p<0.01). PMID 23417317 Wang Y et al. Am J Clin Dermatol. 2013.
  • Multicenter study (n=60, 3:1 ratio): anti-wrinkle efficiency 48.9% in Argireline group; wrinkle depth notably reduced (p<0.01). In aged mice, type I collagen increased (p<0.01) and type III decreased (p<0.05) after twice-daily application for 6 weeks. PMID 23607739 Wang Y et al. J Cosmet Laser Ther. 2013.
  • Double-blind pilot study (n=19 females). Wrinkle scores decreased non-significantly after 4 weeks of once-morning/once-evening serum application (right side p=0.060, left side p=0.176). The effect of Argireline was not statistically proven; no significant adverse events. PMID 38024099 Henseler H. GMS Interdiscip Plast Reconstr Surg DGPW. 2023.
  • In aged D-galactose mice, twice-daily topical Argireline for 6 weeks improved histological skin structure: type I collagen increased (p<0.01) and type III collagen decreased (p<0.05). PMID 23464592 Wang Y et al. J Cosmet Laser Ther. 2013.
• Blepharospasm (adjunct to botulinum toxin therapy) Human RCT
  • Double-blind, placebo-controlled RCT (n=24 BSP patients). Daily topical AH8 showed a trend for longer time to return to baseline Jankovic BSP Rating Scale after BoNT injection (3.7 months active vs 3.0 months placebo). No significant adverse events. One-third of active-group patients had considerable extension of sympt PMID 23146065 Lungu C et al. Eur J Neurol. 2013.
• Skin scar and wrinkle camouflage / cosmeceutical use in skin disorders Human observational
  • Retrospective study (n=26) using a gelcream containing 10% acetyl hexapeptide-8. Significant improvement in skin hydration, elasticity, sebum, and self-image expectation. No allergic reactions documented. PMID 33151254 Palmieri B et al. Clin Ter. 2020.
• Anti-aging and skin rejuvenation (combination with fractional laser for striae distensae) Human observational
  • Pilot study (n=10) evaluating a tripeptide/hexapeptide serum as adjunct to 1540 nm non-ablative fractional laser for striae distensae. All patients reported subjective improvement; addition of serum increased objective improvement, reduced post-inflammatory hyperpigmentation, and increased patient satisfaction. PMID 33397562 McGuinn KP et al. Skinmed. 2020.
• Antiwrinkle and neuromuscular signaling inhibition via transdermal delivery systems Mixed
  • A synergistic transdermal delivery system combining self-assembled nanoparticles (DAC-SAP) including Argireline and a ternary deep eutectic solvent (BGP). In vitro, in vivo, and exploratory clinical assessments demonstrated inhibition of sodium/calcium channel activity, reduced ACh secretion, and improved skin elastici PMID 42202650 Bai D et al. Biomater Adv. 2026.
  • Argireline (Arg0) in propylene glycol/water co-solvents applied in vitro; modified analogue Arg3 showed the most effective inhibition of glutamate release from neurons and enhanced skin permeation. Original Arg0 has poor skin permeation due to large molecular weight and hydrophilicity (zwitterionic form). PMID 29371611 Lim SH et al. Sci Rep. 2018.
• Collagen remodeling / dermal biology effects (injectable, animal model) Animal studies only
  • In female Wistar rats (n=40), subdermal injection of Argireline produced a collagen profile indistinguishable from saline control (no significant shift in type I/III collagen or Substance P). Injectable Argireline produced no detectable tissue-level effect under tested conditions. PMID 42675285 Acuner B et al. Aesthetic Plast Surg. 2026.
• Moisturizing, anti-inflammatory, and antioxidant bioactivities Animal studies only
  • In zebrafish embryo models, ARG (containing 0.125% acetyl hexapeptide-8) reduced caudal fin water loss, alleviated UVB-induced reduction of skin tightness genes (ELN/COL1a1b), reversed β-galactosidase activity increases, counteracted oxidative stress and mitochondrial damage, and suppressed neutrophil counts and inflam PMID 40176351 Jiang X et al. J Cosmet Dermatol. 2025.
• Photoaging treatment (topical cosmeceutical peptide) Mixed
  • Systematic review concluded that the evidence base behind topical peptides, including Argireline, for photoaging treatment is among the strongest of all cosmeceuticals reviewed, with most studies achieving Level Ib status in the evidence hierarchy. PMID 39233460 Chan LKW et al. Skin Res Technol. 2024.
• Skin penetration / transdermal delivery research In vitro only
  • 10% Ac-EEMQRR-amide O/W emulsion applied at 2 mg/cm² to hairless guinea pig and human cadaver skin. Majority washed from surface; peptide remaining in stratum corneum: 0.54% (HGP) and 0.22% (human). No peptide detected in dermis or receptor buffer. No metabolites detected. PMID 24754410 Kraeling MEK et al. Cutan Ocul Toxicol. 2015.
  • W/O/W multiple emulsion significantly increased AH-8 penetration into porcine skin compared to simple O/W and W/O emulsions. Water-rich emulsions superior to oil-rich W/O emulsions for dermal delivery. PMID 25786877 Hoppel M et al. Eur J Pharm Sci. 2015.
  • Iontophoresis increased Argireline® (MW 889 Da) permeation through excised human skin up to 30-fold relative to passive permeation. Electroosmosis was an important flux determinant. Higher donor concentration (1–10 mg/mL) increased permeation 2–4-fold. Extra background electrolyte decreased iontophoretic permeation coe PMID 25497319 Krishnan G et al. Drug Deliv Transl Res. 2014.
• Cu(II) chelation and coordination chemistry (cosmetic derivative research) In vitro only
  • Argireline and three novel derivatives (AN4, AN5, AN6) were characterized for Cu(II) chelating properties via potentiometric titration and isothermal titration calorimetry. DFT calculations proposed Cu-peptide complex structures. Cytotoxicity of free peptides and Cu(II) complexes was estimated in human skin cells. PMID 37752675 Wyrzykowski D et al. J Pept Sci. 2024.
• Controlled release via polydioxanone (PDO) suture delivery system In vitro only
  • PDO threads soaked in Argireline absorbed peptide by capillarity and demonstrated sustained release for approximately 1 hour by UV spectroscopy. Thread weight doubled every 24 h without premature physical degradation. Proposed as a controlled-release system for deep static facial wrinkles; authors recommended clinical PMID 38314369 Velazco de Maldonado GJ et al. J Cutan Aesthet Surg. 2023.
• 3D skeletal muscle tissue model for drug/cosmetic testing In vitro only
  • Argireline® Amplified peptide caused muscle relaxation effects in 3D-bioengineered human skeletal muscle tissue treated with TNF-α to mimic aging conditions, demonstrating the platform's utility for cosmetic ingredient evaluation. PMID 34284359 Mestre R et al. Biofabrication. 2021.

Community-reported dosing

Tier key: Research = PMID-cited study · [C] = scraped community source · [S] = model-synthesized from aggregate community reports (softer evidence). How we source.

Safety signals

• Mycobacterium abscessus infection at argireline injection sites (erythema, nodules, abscesses) in a 45-year-old woman after forehead and temple injections; required 5 months of dual antibiotic therapy. PMID 33748252
• Dose-dependent cytotoxicity (anti-proliferative effects) observed in vitro in HEK-293, IMR-32 neuroblastoma, and primary skin fibroblast cell lines; significant cytotoxicity at 18- to 10,000-fold higher concentrations than doxorubicin (reference cytotoxic compound). PMID 24644551
• Cytotoxicity in HaCaT human keratinocyte cells observed at lower concentrations compared to Reishi extract reference, suggesting a narrower in vitro safety margin. PMID 41657122
• No significant adverse events, allergic reactions, or skin irritations reported in a double-blind pilot topical study (n=19 females, 4 weeks). PMID 38024099
• No allergic reactions documented during topical gelcream (10% AH8) treatment in 26 patients with skin disorders. PMID 33151254
• No significant adverse events reported in a double-blind RCT of daily topical AH8 in 24 blepharospasm patients over several months. PMID 23146065
• No in vivo oral toxicity or primary irritation observed at high doses in original seminal study. PMID 18498523

Contraindications

• No specific contraindications are explicitly stated in the reviewed abstracts. The case report of Mycobacterium abscessus infection following injection implies that injectable use poses infection risk, particularly without standardized sterile technique. PMID 33748252